Popular on Amzeal
- Elixia Announces New Hire Sam Searcy as Chief Commercial Officer
- New "Perfect Home Finder" Real Estate Program Huge Hit With Central OH Home Buyers!
- 3 Lessons Learned From The Presley Trust
- The Heavenly Collection of Phygital Error Coinage by Mylathecos™ Upcoming Media And Museum Presence
- Central Ohio Realtor Introduces New Marketing For Better Prices In Difficult Market
- Accendo's Talent Intelligence Platform Secures Pre-Series A Funding from The Hive SEA and OSK Ventures
- Guaranteed Full Price Home Sale in Phoenix West Valley! Sell Your House For Top Dollar Without The Hassle of Listing or Showings!
- "Not Going Quietly" Wins Cinema for Peace Award for Political Film of the Year 2022 in Berlin
- Phoreus Biotech launches BAPtofect®-25 peptide transfection reagent
- Luxury Presence Announces New Chief Customer Officer
Similar on Amzeal
- Critical Component of The Restorative Soils Program™ Patented!
- Universal Sequencing Technology Corporation Launches High-Throughput Solution For Microbial WGS Library Preparation
- Optical Computing for Object Classification Through Diffusive Random Media
- 43rd International Symposium on Forecasting – Dates, Venue and Speakers Announced
- "Einstein: The Man and His Mind" wins the Reader Views Grand Prize Gold Award in Non-Fiction
- AI-based staining of biological samples
- Elixia Announces New Hire Sam Searcy as Chief Commercial Officer
- BioSafe Systems Celebrates 25 Years of Positive Change
- Latest research shows Australians still not getting annual skin checks with a Health Professional
Phoreus Biotech launches BAPtofect®-25 peptide transfection reagent
Amzeal News/10516410
The new product offers a superior alternative to industry-leading, lipid-based reagents
OLATHE, Kan. - Amzeal -- Phoreus Biotech, a leading provider of next-generation peptide nanocarriers, announced today they've added a new product to their portfolio of proprietary transfection reagents. The new BAPtofect-25 for general cell transfection now allows researchers to work with a large variety of cell lines to compliment the company's previous offerings for use in insect cell lines.
"Researchers have been stuck for too long with using lipid-based transfection reagents that can be very cytotoxic," said Michael Coe, CSO, Phoreus Biotech. "We're pleased to present a new option that has a number of advantages over the leading reagents available today."
Cell transfection is the process of introducing DNA, RNA, or other genetic material into cells to modify or activate those cells. It is a critical step in many areas of research, from gene therapy to vaccine development. Phoreus Biotech has been a provider of transfection reagents for more than four years, and they continue to expand their portfolio with innovative products like BAPtofect-25. This new product allows researchers to work with numerous difficult-to-transfect cell lines, making it an essential tool for any lab working in this field.
More on Amzeal News
The lipid-based transfection reagents that have long served as the industry standard suffer from several serious limitations. While liposomal-based carriers can achieve high transfection rates, there are multiple issues associated with their use in research. Lipid-based carriers tend to be unstable, resulting in a premature breakdown that releases their cargo before reaching the intended destination. Additionally, liposomes can sometimes form aggregates and precipitate out of solution or clump together instead of remaining evenly dispersed throughout the solution. Due to their lack of stability and inherent toxicity to cells, there remains a strong need for better transfection reagent options.
BAPtofect-25 provides extremely high transfection rates, compared to the leading liposomal-based carriers, with expression in nearly all cells. The product also maintains excellent cell viability with virtually no cellular toxicity. Users typically see diffuse transfection in cells, rather than the pinpoint transfection of other reagents. BAPtofect-25 also offers the distinct advantage of being able to move seamlessly from in-vitro research to in-vivo applications, unlike the lipid transfection reagents which differ significantly from the lipid nanoparticles used in modern mRNA vaccines. Phoreus nanocarriers have now been referenced in more than 25 research publications for effective in vitro and in vivo nanodelivery.
More on Amzeal News
"We are fully committed to providing researchers with the best possible tools to improve the important work they conduct every day," said Steve Schram, CEO, Phoreus Biotech. "BAPtofect-25 is another example of that commitment."
About Phoreus Biotech
Phoreus Biotech is an Olathe, KS-based life science company and is the provider of three proprietary nanocarrier platforms with the capacity to revolutionize human, animal, plant, and environmental health. Their Branched Amphipathic Peptide Capsules (BAPC®), Corralling Amphipathic Peptide Capsules (CAPC®), and Amphipathic Peptide Capsules (APC®) offer substantially increased efficacy in the creation and delivery of vaccines, cancer therapies, antibiotics, diagnostics, and biopesticides.
"Researchers have been stuck for too long with using lipid-based transfection reagents that can be very cytotoxic," said Michael Coe, CSO, Phoreus Biotech. "We're pleased to present a new option that has a number of advantages over the leading reagents available today."
Cell transfection is the process of introducing DNA, RNA, or other genetic material into cells to modify or activate those cells. It is a critical step in many areas of research, from gene therapy to vaccine development. Phoreus Biotech has been a provider of transfection reagents for more than four years, and they continue to expand their portfolio with innovative products like BAPtofect-25. This new product allows researchers to work with numerous difficult-to-transfect cell lines, making it an essential tool for any lab working in this field.
More on Amzeal News
- Exhibiting Our Robot Lucki at the Georgia Restaurant Association Taste of Georgia Event 2023
- Keyhole Software Ranked Top Software Development and IT Services Company in Kansas City by Clutch
- PEI Launches Revamped Guide on Working with a Managed Services Provider
- EZDorms Research Releases 2023 Survey Results
- Levinger Regens Announces New Initiative to Improve Hydrogen Carbon Intensity
The lipid-based transfection reagents that have long served as the industry standard suffer from several serious limitations. While liposomal-based carriers can achieve high transfection rates, there are multiple issues associated with their use in research. Lipid-based carriers tend to be unstable, resulting in a premature breakdown that releases their cargo before reaching the intended destination. Additionally, liposomes can sometimes form aggregates and precipitate out of solution or clump together instead of remaining evenly dispersed throughout the solution. Due to their lack of stability and inherent toxicity to cells, there remains a strong need for better transfection reagent options.
BAPtofect-25 provides extremely high transfection rates, compared to the leading liposomal-based carriers, with expression in nearly all cells. The product also maintains excellent cell viability with virtually no cellular toxicity. Users typically see diffuse transfection in cells, rather than the pinpoint transfection of other reagents. BAPtofect-25 also offers the distinct advantage of being able to move seamlessly from in-vitro research to in-vivo applications, unlike the lipid transfection reagents which differ significantly from the lipid nanoparticles used in modern mRNA vaccines. Phoreus nanocarriers have now been referenced in more than 25 research publications for effective in vitro and in vivo nanodelivery.
More on Amzeal News
- Eve Wellness, a SF Breast Ultrasound Screening Clinic supports the recent FDA updates to the guidelines to inform women about breast density
- Expert tip: Private Jet Engine Maintenance Program - Pros and Cons for Preowned Jet Buyers
- Gaming and entertainment company Spinrack Corporation, appoints Jesse Norton as Chief Marketing Officer
- iGUIDE and Seek Now Have Partnered with AMS and VITALITY to Bring a Comprehensive Solution to Facility Managers
- .Store Domains launches Elevate.store – a free-to-use platform for online sellers with deals on business tools
"We are fully committed to providing researchers with the best possible tools to improve the important work they conduct every day," said Steve Schram, CEO, Phoreus Biotech. "BAPtofect-25 is another example of that commitment."
About Phoreus Biotech
Phoreus Biotech is an Olathe, KS-based life science company and is the provider of three proprietary nanocarrier platforms with the capacity to revolutionize human, animal, plant, and environmental health. Their Branched Amphipathic Peptide Capsules (BAPC®), Corralling Amphipathic Peptide Capsules (CAPC®), and Amphipathic Peptide Capsules (APC®) offer substantially increased efficacy in the creation and delivery of vaccines, cancer therapies, antibiotics, diagnostics, and biopesticides.
Source: Phoreus Biotech
Filed Under: Science
0 Comments
Latest on Amzeal News
- The Past Reflects A Future - Daniel Imperato 2024 Is Back Again. Which Party?
- Fridge Art Fair New York City May 2023
- Empowering SMEs: Innervation's Supply Chain Finance Solutions for Diverse Business Growth
- AdvisorVault Partners With Compliant Workspace to Help FINRA Firms Achieve 17a-4 Compliance on Microsoft 365
- Why Do Canada's Privacy Commissioners Demand that Companies Train Employees on Security and Privacy?
- Luxury Presence Among HousingWire's 2023 Tech100 Real Estate Winners
- Axiomtek Debut New NVIDIA Jetson Orin Platform – AIE900A-AO & AIE100A-ONX At Embedded World 2023
- The New Real Estate "Just Looking" Program Is A Big Hit With Atlanta Area Residents!
- Introducing Music360, the New Social Music Streaming App
- Marsha Gay Reynolds Shares Insights on In-Home Care Post-Pandemic
- Your Housing Group boosts Field Force Efficiency and Resident Experience with FLS
- IOTech announces a new release of Edge Xrt, its high performance data connectivity solution for industrial systems
- Barcoding, Inc. Showcases Freddie AGV (Automated Guided Vehicle) Robot at Promat 2023
- ANIMAL RIGHTS PROTEST at The Animal Foundation of Las Vegas
- Vigil Family Foundation (VFF) Offers Northern New Mexico Students Renewable Energy Scholarships
- Graphis to Publish Kit Hinrichs' New Book: Narrative Design
- Looming ban threats of TikTok Causes Uncertainty For Creators - New Platform Brings Hope
- The expansion continues at Right Cars Global Rentals as it officially announces its opening in the Dominican Republic
- Critical Component of The Restorative Soils Program™ Patented!
- King Me: Loving and Leading in a Wounding World Releases March 15, 2023